In-Vitro Toxicology Testing Market to Hit $18.6 billion by 2027

The in vitro toxicology testing market is projected to reach USD 18.6 billion by 2027 from USD 11.2 billion in 2022, at a CAGR of 10.8%

According to a research report titled "In Vitro Toxicology Testing Market by Product (Assays, Equipment, Consumables, Software), Toxicity Endpoints, Technology, Method, and Industry - Global Forecast to 2027" published by MarketsandMarkets, the in vitro toxicology testing market is projected to reach USD 18.6 billion by 2027, with a CAGR of 10.8% during the forecast period. The primary growth drivers for this market are technological advancements and increasing RD expenditure aimed at early-stage detection of toxicity during drug development.

Download PDF Brochure:

The development of toxicology databases for in-silico studies of various chemicals is expected to drive the demand for in vitro methods and advance the industry. Manufacturers have taken significant steps to enhance patient access to diagnostic testing, vaccine and drug development in laboratories, hospitals, and testing sites worldwide, ensuring better patient care and public health protection.

In terms of product and service, the consumables segment is anticipated to account for the largest market share. The segment's growth is attributed to the increasing demand for high-quality reagents and the repeated use of media and reagents in in vitro toxicology studies. The growing demand for customized media for toxicology studies will further drive the growth of this segment.

The organ toxicity segment is expected to experience the highest growth in the toxicity endpoints and tests market during the forecast period. The increasing focus on drug and consumer-product safety is driving the growth in this segment. Early-stage screening for organ-specific toxicity enables the identification of better drug candidates with a higher likelihood of becoming therapeutic drugs.

Among the technologies used in in vitro toxicology testing, the cell culture technologies segment is projected to account for the largest market share. Cell culture technologies are commonly employed in pharmacology for in vitro toxicology testing. Bacterial or mammalian cell cultures can express the same genes and proteins as their in vivo counterparts, providing similar testing environments. This factor is driving the growth of the cell culture technologies segment.

The Asia Pacific region is estimated to be the fastest-growing market for in vitro toxicology testing during the forecast period. Factors such as opposition to animal testing, the emergence of contract research organizations (CROs) for outsourcing toxicology-related research projects, increasing consumer awareness of product safety, and a growing pharmaceutical drug pipeline contribute to the market's growth in the region. The Asia Pacific is also becoming a major destination for drug development and clinical research due to cost advantages, a large treatment-naïve population, participant retention in clinical trials, and improving regulatory procedures.

Get 10% Customization:

Prominent players in the in vitro toxicology testing market include Thermo Fisher Scientific, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, General Electric Company, Eurofins Scientific, Merck KGaA, Charles River Laboratories International, Catalent, Evotec, SGS S.A., QIAGEN, Promega Corporation, Gentronix Limited, BioIVT, and MB Research Laboratories.

Related links:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Healthcare News

152 Blog posts